In May 2026, the company announced multi-site clinical validation results for its TAEUS® Liver device demonstrating strong agreement with MRI-PDFF, high reproducibility and consistent performance across operators, sites and patient populations. However, on March 25, 2026, the Board of Directors initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value, signaling potential inflection or structural challenges despite clinical progress.
Cyborg Score Rationale
ENDRA demonstrates solid clinical validation of its core TAEUS technology with reproducible multi-site evidence (May 2026). However, the March 2026 strategic alternatives review suggests value-creation uncertainty, and the stock trades near $5.94 with a negative earnings profile and minimal scale. Technology differentiation exists but commercialization and market adoption remain unproven.
Top Insights
As of July 21, 2026, ENDRA trades at $5.94 with a market cap of $6.81M, indicating minimal financial scale despite NASDAQ listing. Clinical progress alone has failed to drive institutional traction or sustained equity value.
TAEUS Liver clinical validation (May 2026) shows technical feasibility and reproducibility versus MRI gold standard, addressing a critical proof-point for regulatory and commercial viability in non-invasive liver fibrosis assessment.
Strategic alternatives review initiated March 2026 suggests board belief that standalone path faces capital, scale, or partnering constraints. No timetable announced; execution risk remains high through remainder of 2026.
Named Competitors
FibroScan — Transient elastography for non-invasive liver fibrosis assessment
LiverOnScreen — AI-enhanced ultrasound software for non-invasive liver steatosis quantification
MR Elastography — MRI-based elastography for non-invasive assessment of liver fibrosis and steatosis